Cover Image
市場調查報告書

Sarilumab (類風濕性關節炎) - 2023年為止的預測與市場分析

Sarilumab (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 258667
出版日期 內容資訊 英文 87 Pages
訂單完成後即時交付
價格
Back to Top
Sarilumab (類風濕性關節炎) - 2023年為止的預測與市場分析 Sarilumab (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023
出版日期: 2014年12月31日 內容資訊: 英文 87 Pages
簡介

類風濕性關節炎 (RA) 是慢性自體免疫疾病,會引發關節發炎及變形。全球主要10國(美國、法國、德國、義大利、西班牙、英國、日本、澳洲、中國、印度) 患者數超過了700萬人,預測到2023年前達到850萬人。之前TNF抑制劑雖然對RA的徵兆和症狀都有效,但由於引進生技仿製藥、新生技藥品、口服的JAK抑制劑等,市場情勢正在急速變化。

本報告提供RA治療藥物──Sarilumab之調查分析,提供您疾病概要和治療指南、競爭情形、產品資訊、銷售額預測等相關的系統性資訊。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因·病理生理學
  • 症狀
  • 預後
  • QOL

第4章 疾病的管理

  • 診斷和治療概要
    • 診斷
    • 治療指南
    • 主要的處方藥
    • 臨床診療

第5章 競爭評估

  • 概要

第6章 未滿足需求和機會

  • 概要
  • 開發高成本效益之治療法
  • 預測生物標記治療的反應性
  • RA的早期診斷
  • 個人化醫療法

第7章 開發平台評估

  • 概要
  • 臨床開發中的潛力藥物

第8章 Sarilumab

  • 概要
  • 功效
  • 安全性
  • 給藥·處方
  • 潛在的臨床性地位
  • 潛在的商業性地位
  • 價格與給付
  • SWOT分析
  • 預測

第9章 附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC504DFR

Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints . It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With the anti-TNFs as extremely effective therapies for RA, the market is extremely competitive for new entrants and will undergo further pressure as biosimilars are approved and launch.

Regeneron and Sanofi's sarilumab is the first fully-human mAb against IL-6, and is in Phase III of development for RA. Sarilumab is directed against IL-6R and reduces inflammation, thus preventing the joint damage that is common in RA. Although Actemra is an anti-IL6 mAb currently approved for RA, this biologic agent is a recombinant human mAb and does not offer the same safety advantages of a fully-human mAb.

Scope

  • Overview of Rheumatoid Arthritis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Sarilumab including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Sarilumab for the top 8 countries from 2013 to 2023.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return.
  • Stay ahead of the competition by understanding the changing competitive landscape for Rheumatoid Arthritis.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
  • Make more informed business decisions from insightful and in-depth analysis of Sarilumab performance.
  • Obtain sales forecast for Sarilumab from 2013-2023 in top 8 countries (the US, France, Germany, Italy, Spain, the UK and Japan and Australia).

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Symptoms
  • 3.3. Prognosis
  • 3.4. Quality of Life

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Diagnosis
    • 4.1.2. Treatment Guidelines
    • 4.1.3. Leading Prescribed Drugs for the Treatment of RA
    • 4.1.4. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview

6. Unmet Need and Opportunity

  • 6.1. Overview
  • 6.2. Development of Cost-Effective Therapies
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Biomarkers to Predict Responsiveness to Therapy
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Early Diagnosis of RA
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Personalized Treatment Approach
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Drugs in Clinical Development

8. Sarilumab

  • 8.1. Overview
  • 8.2. Efficacy
  • 8.3. Safety
  • 8.4. Dosing and Formulation
  • 8.5. Potential Clinical Positioning
  • 8.6. Potential Commercial Positioning
  • 8.7. Pricing and Reimbursement

8.8. SWOT Analysis

  • 8.9. Forecast

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed RA Patients
    • 9.4.2. Percentage of Drug-Treated Patients
    • 9.4.3. General Pricing Assumptions
    • 9.4.4. Generic and Biosimilar Erosion
    • 9.4.5. Pricing of Pipeline Agents
  • 9.5. Primary Research - KOLs Interviewed for This Report
  • 9.6. Primary Research - Prescriber Survey
  • 9.7. About the Authors
    • 9.7.1. Analyst
    • 9.7.2. Reviewer
    • 9.7.3. Therapy Area Director
    • 9.7.4. Global Head of Healthcare
  • 9.8. About GlobalData
  • 9.9. Disclaimer

List of Tables

  • Table 1: Symptoms of RA
  • Table 2: 1987 ACR Diagnostic Criteria for RA
  • Table 3: 2010 ACR/EULAR Diagnostic Criteria for RA
  • Table 4: Treatment Guidelines for RA Used by Each Country in the 10MM
  • Table 5: ACR 2012 Criteria for RA Remission and Low/Moderate/High Disease Activity
  • Table 6: EULAR 2013 Criteria for RA Remission
  • Table 7: Most Prescribed Biologics for RA (After csDMARDs) in the Global Markets, 2014
  • Table 8: Leading Branded Treatments for RA 2014
  • Table 9: Unmet Need and Opportunity in RA, 2014
  • Table 10: Comparison of Therapeutic Drug Classes in Development for RA, 2014
  • Table 11: Product Profile - Sarilumab
  • Table 12: MOBILITY Study Part, A, Results for Sarilumab at Week 12
  • Table 13: MOBILITY Study, Part B, Results for Sarilumab at Week 52
  • Table 14: Sarilumab SWOT Analysis, 2014
  • Table 15: Global Sales Forecasts ($m) for Sarilumab, 2013-2023
  • Table 16: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1: Normal Synovial Joint and Synovial Joint with RA
  • Figure 2: Cellular and Cytokine Targets for the Current RA Drugs
  • Figure 3: Disease Management Flowchart for Early RA - ACR 2012
  • Figure 4: Disease Management Flowchart for Established RA - ACR 2012
  • Figure 5: Flowchart for the Management of RA - EULAR 2013
  • Figure 6: RA - Phase II-III Pipeline, 2014
  • Figure 7: Competitive Assessment of Late-Stage Pipeline Agents in RA, 2013-2023
  • Figure 8: Clinical and Commercial Positioning of Sarilumab
Back to Top